- The Fiscal Times•2 hours ago
Pfizer Inc., the world’s largest drug manufacturer, is no stranger to the growing controversy over price gouging and anti-competitive practices that have drawn sharp criticism from President Trump and prompted calls for government intervention. Last December, for example, Pfizer and Flynn Pharma Ltd. were hit with record fines totaling more than $110 million in Great Britain after they were found to have conspired to increase prices by as much as 2,600 percent for unbranded versions of the anti-epilepsy drug Epanutin.
- Business Wire•5 hours ago
XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA)
Pfizer Inc. announced today that the European Commission has approved XELJANZ® 5 mg twice daily oral tablets in combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs .
- Motley Fool•yesterday
Diabetes patients could have new treatment options if Merck, Pfizer, Lexicon, Sanofi, and Novo Nordisk succeed with these three promising drugs.
PFE : Summary for Pfizer, Inc. - Yahoo Finance
Pfizer Inc. (PFE)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||33.75 - 34.10|
|52 Week Range||29.41 - 37.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||29.04|
|Dividend & Yield||1.28 (3.76%)|
|1y Target Est||N/A|